Melrose Industries Outperforms Expectations, Raises Aerospace Guidance

1 Mins read

Melrose Industries has reported that it is performing ahead of expectations, leading to an increase in its aerospace guidance for the year. The London-listed turnaround specialist cited higher aftermarket demand and pricing, as well as operational improvements, as key factors driving its strong performance.

During the period from July 1 to Oct. 31, Melrose Industries experienced an 18% increase in revenue, with underlying demand also showing positive growth. As a result of stronger underlying margins, the company has raised its profit expectations for 2023 by 7%. This will more than double profits compared to the previous year.

The engines division saw revenue growth at 18% and achieved adjusted operating margins of over 25%. This impressive performance was partly driven by a 24% increase in aftermarket trading.

Looking forward to 2023 and beyond, Melrose Industries expects adjusted operating profit in the aerospace division to range between £400 million and £410 million ($496.7 million to $509.1 million). This exceeds the previous guidance of £375 million to £385 million. Group revenue is projected to be between £3.3 billion and £3.4 billion. For 2024, revenue is expected to fall between £3.5 billion and £3.7 billion, with the aerospace division anticipating adjusted operating profit in the range of £520 million to £540 million and an adjusted operating margin of around 15%.

Melrose Industries expressed confidence in the ongoing performance of the business, stating that significant operational improvements are being made in both Engines and Structures divisions to further enhance margins.

Shares of Melrose Industries rose 6 pence, or 1.1%, reaching 538.60 pence at 0822 GMT.

Related posts

GitLab Stock Surges on First Ever Adjusted Operating Profit

1 Mins read
GitLab’s stock experienced a significant surge on Tuesday following the announcement of its first ever adjusted operating profit. Despite this positive development,…

Virgin Galactic Faces Stock Decline Amid Founder's Money Decision

2 Mins read
Virgin Galactic stock experienced a sharp decline in early trading on Monday due to founder Richard Branson’s announcement that he won’t be…

EyePoint Pharmaceuticals Announces Positive Results in Phase 2 Trial for Macular Degeneration Treatment

1 Mins read
EyePoint Pharmaceuticals, a Massachusetts-based company, revealed exciting news on Monday regarding the second-phase trial of its investigational treatment for macular degeneration. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

+ 70 = 71